

#3 03/26/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Mesens *et al.*

Appl. No. To be assigned  
(Continuation of Appln. No. 09/005,549)

Filed: Herewith

For: Microencapsulated 3-Piperidinyl-  
Substituted 1,2-Benzisoxazoles and  
1,2-Benzisothiazoles

Art Unit: To be assigned

Examiner: To be assigned

Atty. Docket: 00166.0051.US04



**Information Disclosure Statement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of the documents were previously cited or submitted in Applicants 35 U.S.C. § 120 priority Application No. **09/005,549**, filed **January 12, 1998**, Application No. **08/808,261**, filed **February 28, 1997** and priority Application No. **08/154,403**, filed **November 19, 1993**. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

The Examiner is also referred to the following list of related, co-pending patent applications:

Appl. No. 08/154,403, filed November 19, 1993;

Appl. No. 08/808,261, filed February 28, 1997; and

Appl. No. 09/005,549, filed January 12, 1998.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.


Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449 and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038.

Respectfully submitted,

A handwritten signature in black ink, reading "Andrea G. Reister". The signature is fluid and cursive, with the first name "Andrea" and last name "Reister" clearly legible.

Andrea G. Reister (Reg. No. 36,253)

Date: February 18, 1991

HOWREY & SIMON  
Box No. 34  
1299 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004-2402  
(202) 783-0800